Prostate Cancer - Results from #220

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. November 11, 2024

Advanced Imaging for Localized Prostate Cancer. November 11, 2024

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment November 8, 2024

5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. November 8, 2024

The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619. November 8, 2024

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer. November 8, 2024

Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer. November 8, 2024

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. November 8, 2024

The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial. November 8, 2024

Multidimensional Healthcare Access Barriers to Prostate-Specific Antigen Testing: A Nation-Wide Panel Study in the United States From 2006 to 2020. November 7, 2024

Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy. November 7, 2024

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. November 7, 2024

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection. November 7, 2024

PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide. November 7, 2024

Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC). November 6, 2024

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer. November 6, 2024

Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial. November 6, 2024

Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts. November 6, 2024

AI-ADC: Channel and Spatial Attention-Based Contrastive Learning to Generate ADC Maps from T2W MRI for Prostate Cancer Detection. November 6, 2024

Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer. November 6, 2024

Page 12 of 1447